Research programme: neurological disorder theraputics - ReNetX Bio
Latest Information Update: 24 Nov 2022
At a glance
- Originator ReNetX Bio
- Class Recombinant fusion proteins
- Mechanism of Action Myelin-associated glycoprotein inhibitors; Nogo protein inhibitors; Oligodendrocyte myelin glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diffuse brain injuries; Multiple sclerosis; Neurodegenerative disorders
Most Recent Events
- 21 Nov 2022 Preclinical trials in CNS disorders in USA (Parenteral) (Renetx Bio pipeline, November 2022)
- 21 Nov 2022 Preclinical trials in Diffuse brain injuries in USA (unspecified route) (Renetx Bio pipeline, November 2022)
- 21 Nov 2022 Preclinical trials in Multiple sclerosis in USA (Parenteral) (Renetx Bio pipeline, November 2022)